Trump urged to launch a fast-track program for regenerative medicine

The article warns that China’s massive investment in biotech, especially regenerative medicine, threatens U.S. dominance in a sector projected to grow to over $360 billion by 2034. It contends that America’s strengths—top research institutions, venture capital, and biotech firms—are undermined by slow translation of discoveries into approved therapies. Drawing on the success of Operation Warp Speed, the author urges President Donald Trump to establish a comparable effort for regenerative medicine, focusing on modernized trial designs, expanded translational research, domestic production, and clear regulatory routes.

The editorial highlights how such therapies could cut chronic-disease costs and support the administration’s “Make America Healthy Again” agenda. It also notes a recent clinical trial by Crescel LLC that demonstrated superior results for rosacea using a biobotanical formulation. The overall message is that proactive policy is needed to keep the next wave of medical innovation in American hands.